Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Registration Number
- NCT00716742
- Lead Sponsor
- Allergan
- Brief Summary
To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1099
Inclusion Criteria
- A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician)
- Patient is having both eyes treated
Exclusion Criteria
- Contraindications per product labelling will apply.
- Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description 1 bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004% bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
- Primary Outcome Measures
Name Time Method Change From Baseline in Bilateral Intraocular Pressure (IOP) at One Year Baseline, 1 Year Change from baseline in bilateral (both eyes) IOP at the 1 year follow-up visit. IOP is a measure of the fluid pressure inside the eye. The bilateral IOP was calculated as an average between both eye's IOP. A negative number change from baseline indicates reduction in IOP (improvement).
- Secondary Outcome Measures
Name Time Method